Advertisement
U.S. markets closed

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.9400+0.0300 (+0.61%)
At close: 04:00PM EST
4.8900 -0.05 (-1.01%)
After hours: 06:53PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Long-term KST

Long-term KST

Previous Close4.9100
Open4.9250
Bid4.8600 x 1100
Ask4.9100 x 3100
Day's Range4.8800 - 5.0700
52 Week Range2.2300 - 6.8900
Volume1,384,771
Avg. Volume3,075,836
Market Cap831.288M
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-2.2000
Earnings DateMay 01, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ALLO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Allogene Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/18/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 6:10 a.m. PT/9:10 a.m. ET. Any available webcasts will be posted to the Company's website at www.allogene

  • GlobeNewswire

    Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

    No Impact on Cash, Cash Equivalents and Marketable Investments, Cash Runway or Business OperationsCompany Targeting On or Before March 14, 2024 to File Amended Financial Statements and Report Fourth Quarter and Full Year 2023 Financial Results SOUTH SAN FRANCISCO, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today

  • GlobeNewswire

    Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences in January and February. B. Riley Oncology ConferenceThursday, January 18, 202412:30PM PT/3:30PM ET Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceWednesd